Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04172454

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

A Multicenter, Open-label,Phase 1b/2 Study for Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Sponsor: Akeso

Conditions Advanced Solid Tumors Melanoma

Interventions AK104

Updated 6 times since 2019 Last updated: Oct 8, 2022 Started: Dec 20, 2019 Primary completion: Jun 17, 2021 Completion: Sep 23, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Solid Tumors and Melanoma and is currently completed. Akeso leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jul 2022 — Nov 2022 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Dec 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso
Akeso Pharmaceuticals, Inc.

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China